Knockdown of CYP19A1 by specific siRNA significantly impeded growth of orthotopic and subcutaneous MC38 colon cancer, but its combination with anti-PD-1 treatment was far more effective than monotherapy (Fig. 9D-H). This evidence concerns the gene CYP19A1 and malignant colon neoplasm.